Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed


Shares of Boston-based Vertex Pharmaceuticals jumped 21%, to $108.50, in premarket trading on Wednesday after the company on Tuesday night announced successful outcomes from two clinical trials involving tezacaftor, a second-generation "corrector" used in combination therapies to treat the underlying cause of cystic fibrosis. Meanwhile, shares of Sangamo Therapeutics were up 12.4%, to $4.55.



from Biotech News